We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
PharmaGap Lead Drug to be Presented at American Association for Cancer Research 102nd Annual Meeting
Product News

PharmaGap Lead Drug to be Presented at American Association for Cancer Research 102nd Annual Meeting

PharmaGap Lead Drug to be Presented at American Association for Cancer Research 102nd Annual Meeting
Product News

PharmaGap Lead Drug to be Presented at American Association for Cancer Research 102nd Annual Meeting


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "PharmaGap Lead Drug to be Presented at American Association for Cancer Research 102nd Annual Meeting"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

PharmaGap Inc. has announced that the Dr. Ken Sokoll, Vice President Clinical Development and Chief Operating Officer for PharmaGap, along with Dr. Barbara Vanderhyden of the Ottawa Hospital Research Institute, will be presenting results of testing of PharmaGap's lead cancer drug in two separate poster sessions at the American Association for Cancer Research ("AACR") 102nd Annual Meeting in April in Orlando, Florida.

The poster to be presented by PharmaGap is entitled "A Novel PKC inhibitor: Inhibition of Cell Proliferation in Cancer Cell Lines and Pharmacokinetics in Sprague-Dawley Rats". This poster presents further evidence of the ability of GAP-107B8 to inhibit in vitro cell proliferation in various cancer cells.

Using two different routes of administration (single bolus injection and continuous infusion) of GAP-107B8 to Sprague Dawley rats has enabled PharmaGap to gather the first pharmacokinetics data for GAP-107B8 following administration in animals. These data provide insight into important parameters such as the half-life, distribution, metabolism and elimination of GAP-107B8 when administered via the intravenous route.

The poster to be presented by the Barbara Vanderhyden lab at OHRI is entitled "Therapeutic Testing of a Novel Inhibitor GAP-107B8 on Ovarian Cancer Cells", and is the product of the ongoing collaboration among Dr. Vanderhyden, the OHRI, and PharmaGap in developing GAP-107B8 for use in treating ovarian cancer.

In addition to previously announced results from this program showing efficacy against ovarian cancer cell proliferation in both in vitro and in vivo models, the poster will present results indicating the effect of GAP-107B8 in inducing apoptosis (programmed cell death), in blocking or delaying progression of ovarian cancer cells through their normal cell cycle and in the reduction of average tumor size due to its therapeutic efficacy.

The AACR 102nd Annual Meeting 2011 will be held from April 2nd to 6th in Orlando, Florida. The AACR gives exhibitors the opportunity to gain visibility for their organizations among more than 18,000 scientists and other cancer professionals who are projected to attend from around the world, and is considered to be the premier networking event for specialists in all areas of cancer research.

Advertisement